TY - JOUR AU - Usmani, Saad Z. AU - Nahi, Hareth AU - Legiec, Wojciech AU - Grosicki, Sebastian AU - Vorobyev, Vladimir AU - Spicka, Ivan AU - Hungria, Vania AU - Korenkova, Sibirina AU - Bahlis, Nizar J. AU - Flogegard, Max AU - Bladé, Joan AU - Moreau, Philippe AU - Kaiser, Martin AU - Iida, Shinsuke AU - Laubach, Jacob AU - Magen, Hila AU - Cavo, Michele AU - Hulin, Cyrille AU - White, Darrell AU - De Stefano, Valerio AU - Lantz, Kristen AU - O’Rourke, Lisa AU - Heuck, Christoph AU - Delioukina, Maria AU - Qin, Xiang AU - Nnane, Ivo AU - Qi, Ming AU - Mateos, Maria-Victoria PY - 2022/10/01 Y2 - 2024/03/28 TI - Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma JF - Haematologica JA - haematol VL - 107 IS - 10 SE - Articles DO - 10.3324/haematol.2021.279459 UR - https://haematologica.org/article/view/haematol.2021.279459 SP - 2408-2417 AB - In the primary analysis of the phase III COLUMBA study, daratumumab by subcutaneous administration (DARA SC) demonstrated non-inferiority to intravenous administration (DARA IV) for relapsed or refractory multiple myeloma (RRMM). Here, we report the final analysis of efficacy and safety from COLUMBA after a median of 29.3 months follow-up (additional 21.8 months after the primary analysis). In total, 522 patients were randomized (DARA SC, n=263; DARA IV, n=259). With longer follow-up, DARA SC and DARA IV continued to show consistent efficacy and maximum trough daratumumab concentration as compared with the primary analysis. The overall response rate was 43.7% for DARA SC and 39.8% for DARA IV. The maximum mean (standard deviation [SD]) trough concentration (cycle 3, day 1 pre-dose) of serum DARA was 581 (SD, 315) μg/mL for DARA SC and 496 (SD, 231) μg/mL for DARA IV. Median progression-free survival was 5.6 months for DARA SC and 6.1 months for DARA IV; median overall survival was 28.2 months and 25.6 months, respectively. Grade 3/4 treatment-emergent adverse events occurred in 50.8% of patients in the DARA SC group and 52.7% in the DARA IV group; the most common (≥10%) were thrombocytopenia (DARA SC, 14.2%; DARA IV, 13.6%), anemia (13.8%; 15.1%), and neutropenia (13.1%; 7.8%). The safety profile remained consistent with the primary analysis after longer follow-up. In summary, DARA SC and DARA IV continue to demonstrate similar efficacy and safety, with a low rate of infusion-related reactions (12.7% vs. 34.5%, respectively) and shorter administration time (3-5 minutes vs. 3-7 hours) supporting DARA SC as a preferable therapeutic choice. (Clinicaltrials gov. Identifier: NCT03277105. ER -